Identification of NLRP3PYD Homo-Oligomerization Inhibitors with Anti-Inflammatory Activity

Inflammasomes are multiprotein complexes that represent critical elements of the inflammatory response. The dysregulation of the best-characterized complex, the NLRP3 inflammasome, has been linked to the pathogenesis of diseases such as multiple sclerosis, type 2 diabetes mellitus, Alzheimer’s disease, and cancer. While there exist molecular inhibitors specific for the various components of inflammasome complexes, no currently reported inhibitors specifically target NLRP3PYD homo-oligomerization. In the present study, we describe the identification of QM380 and QM381 as NLRP3PYD homo-oligomerization inhibitors after screening small molecules from the MyriaScreen library using a split-luciferase complementation assay. Our results demonstrate that these NLRP3PYD inhibitors interfere with ASC speck formation, inhibit pro-inflammatory cytokine IL1-β release, and decrease pyroptotic cell death. We employed spectroscopic techniques and computational docking analyses with QM380 and QM381 and the PYD domain to confirm the experimental results and predict possible mechanisms underlying the inhibition of NLRP3PYD homo-interactions.

[1]  Mohsen Isazadeh,et al.  Split-luciferase complementary assay of NLRP3 PYD-PYD interaction indicates inflammasome formation during inflammation. , 2021, Analytical biochemistry.

[2]  H. Fearnhead,et al.  Apoptosome Formation through Disruption of the K192-D616 Salt Bridge in the Apaf-1 Closed Form , 2021, ACS omega.

[3]  Kunal Kumar,et al.  Discovery and characterization of small-molecule inhibitors of NLRP3 and NLRC4 inflammasomes , 2021, The Journal of biological chemistry.

[4]  M. Korte,et al.  The NLRP3 inflammasome inhibitor OLT1177 rescues cognitive impairment in a mouse model of Alzheimer’s disease , 2020, Proceedings of the National Academy of Sciences.

[5]  J. Mudgal,et al.  Inhibition of NLRP3-inflammasome mediated IL-1β release by phenylpropanoic acid derivatives: in-silico and in-vitro approach. , 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  H. Fearnhead,et al.  Loss of WD2 subdomain of Apaf-1 forms an apoptosome structure which blocks activation of caspase-3 and caspase-9. , 2020, Biochimie.

[7]  J. MacDonald,et al.  ATP-Binding and Hydrolysis in Inflammasome Activation , 2020, Molecules.

[8]  R. Goldbach-Mansky,et al.  Human Autoinflammatory Diseases Mediated by NLRP3-, Pyrin-, NLRP1-, and NLRC4-Inflammasome Dysregulation Updates on Diagnosis, Treatment, and the Respective Roles of IL-1 and IL-18 , 2020, Frontiers in Immunology.

[9]  V. Hodnik,et al.  Selective inhibition of NLRP3 inflammasome by designed peptide originating from ASC , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  E. Elinav,et al.  Inflammasome activation and regulation: toward a better understanding of complex mechanisms , 2020, Cell Discovery.

[11]  S. Cuzzocrea,et al.  Focus on the Role of NLRP3 Inflammasome in Diseases , 2020, International journal of molecular sciences.

[12]  Elaheh Sadat Hosseini,et al.  The Lumiptosome, an engineered luminescent form of the apoptosome can report cell death by using the same Apaf-1 dependent pathway , 2020, Journal of Cell Science.

[13]  Joo Young Lee,et al.  Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3‐Driven Inflammation and Gouty Arthritis , 2020, Arthritis & rheumatology.

[14]  Yang Wang,et al.  MCC950, a Selective Inhibitor of NLRP3 Inflammasome, Reduces the Inflammatory Response and Improves Neurological Outcomes in Mice Model of Spinal Cord Injury , 2020, Frontiers in Molecular Biosciences.

[15]  Maryam Nikkhah,et al.  Optimization of Experimental Variables Influencing Apoptosome Biosensor in HEK293T Cells , 2020, Sensors.

[16]  Ajay Kumar,et al.  Discovery of benzo[cd]indol-2-one and benzylidene-thiazolidine-2,4-dione as new classes of NLRP3 inflammasome inhibitors via ER-β structure based virtual screening. , 2019, Bioorganic chemistry.

[17]  D. Philpott,et al.  Canonical and noncanonical inflammasomes in intestinal epithelial cells , 2019, Cellular microbiology.

[18]  T. Jin,et al.  Pharmacological Inhibitors of the NLRP3 Inflammasome , 2019, Front. Immunol..

[19]  J. Konvalinka,et al.  MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition , 2019, PLoS biology.

[20]  A. Kwan,et al.  Tryptophan Fluorescence Quenching Assays for Measuring Protein-ligand Binding Affinities: Principles and a Practical Guide. , 2019, Bio-protocol.

[21]  R. Gozalbes,et al.  A new split‐luciferase complementation assay identifies pentachlorophenol as an inhibitor of apoptosome formation , 2019, FEBS open bio.

[22]  C. Day,et al.  MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition , 2019, Nature Chemical Biology.

[23]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[24]  Horacio Pérez-Sánchez,et al.  MCC950 closes the active conformation of NLRP3 to an inactive state , 2019, Nature Chemical Biology.

[25]  Shijun Zhang,et al.  A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury , 2019, Journal of neuroinflammation.

[26]  D. Lane,et al.  Inhibition of NLRP3 inflammasome activation by cell-permeable stapled peptides , 2019, Scientific Reports.

[27]  Houhui Song,et al.  Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors , 2019, Cell Death & Disease.

[28]  Qingsong Liu,et al.  Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity , 2018, Nature Communications.

[29]  G. Turcatti,et al.  Assay for high-throughput screening of inhibitors of the ASC-PYD inflammasome core filament , 2018, Cell stress.

[30]  Elaheh Sadat Hosseini,et al.  Apoptosome formation upon overexpression of native and truncated Apaf-1 in cell-free and cell-based systems , 2018, Archives of biochemistry and biophysics.

[31]  Xianming Deng,et al.  Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases , 2018, EMBO molecular medicine.

[32]  Qingsong Liu,et al.  Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders , 2017, The Journal of experimental medicine.

[33]  S. De,et al.  POP1 might be recruiting its type‐Ia interface for NLRP3‐mediated PYD‐PYD interaction: Insights from MD simulation , 2017, Journal of molecular recognition : JMR.

[34]  N. Kopitar-Jerala The Role of Interferons in Inflammation and Inflammasome Activation , 2017, Front. Immunol..

[35]  F. Meissner,et al.  NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain , 2017, The Journal of experimental medicine.

[36]  S. Yao,et al.  NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies , 2017, Front. Cell. Neurosci..

[37]  G. Rivas,et al.  ASC Pyrin Domain Self-associates and Binds NLRP3 Protein Using Equivalent Binding Interfaces * , 2016, The Journal of Biological Chemistry.

[38]  V. Dixit,et al.  Inflammasomes: mechanism of assembly, regulation and signalling , 2016, Nature Reviews Immunology.

[39]  E. Elinav,et al.  Epithelial IL-18 Equilibrium Controls Barrier Function in Colitis , 2015, Cell.

[40]  C. Sasakawa,et al.  Molecular mechanisms regulating NLRP3 inflammasome activation , 2015, Cellular and Molecular Immunology.

[41]  Anindita Das,et al.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse , 2015, Journal of cardiovascular pharmacology.

[42]  Bertrand Friguet,et al.  NLRP3 inflammasome: From a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases , 2015, Redox biology.

[43]  S. Hosseinkhani,et al.  Split-luciferase complementary assay: applications, recent developments, and future perspectives , 2014, Analytical and Bioanalytical Chemistry.

[44]  F. Sutterwala,et al.  Mechanism of NLRP3 inflammasome activation , 2014, Annals of the New York Academy of Sciences.

[45]  G. Núñez,et al.  3,4-Methylenedioxy-β-nitrostyrene Inhibits NLRP3 Inflammasome Activation by Blocking Assembly of the Inflammasome* , 2013, The Journal of Biological Chemistry.

[46]  O. Beretta,et al.  The NLRP3 inflammasome affects DNA damage responses after oxidative and genotoxic stress in dendritic cells , 2013, European journal of immunology.

[47]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.

[48]  Christoph H. Emmerich,et al.  The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system , 2013, The Biochemical journal.

[49]  S. Hosseinkhani,et al.  Design and development of a whole-cell luminescent biosensor for detection of early-stage of apoptosis. , 2012, Biosensors & bioelectronics.

[50]  K. Tracey,et al.  Novel role of PKR in inflammasome activation and HMGB1 release , 2012, Nature.

[51]  J. Wells,et al.  A small molecule inhibitor of Caspase 1 , 2011 .

[52]  Pedro Romero,et al.  Type I interferon inhibits interleukin-1 production and inflammasome activation. , 2011, Immunity.

[53]  R. Flavell,et al.  Molecular Mechanism of NLRP3 Inflammasome Activation , 2010, Journal of Clinical Immunology.

[54]  E. Alnemri,et al.  Anti-inflammatory Compounds Parthenolide and Bay 11-7082 Are Direct Inhibitors of the Inflammasome* , 2010, The Journal of Biological Chemistry.

[55]  Kate Schroder,et al.  The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.

[56]  J. Ting,et al.  Inflammasome-Associated Nucleotide-Binding Domain, Leucine-Rich Repeat Proteins and Inflammatory Diseases1 , 2009, The Journal of Immunology.

[57]  V. Dixit,et al.  Glyburide inhibits the Cryopyrin/Nalp3 inflammasome , 2009, The Journal of cell biology.

[58]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[59]  B. Cookson,et al.  Pyroptosis: host cell death and inflammation , 2009, Nature Reviews Microbiology.

[60]  Jingfeng Li,et al.  Parthenolide Inhibits IκB Kinase, NF-κB Activation, and Inflammatory Response in Cystic Fibrosis Cells and Mice , 2007 .

[61]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[62]  F. Martinon,et al.  The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.

[63]  S. Srinivasula,et al.  The PYRIN-CARD Protein ASC Is an Activating Adaptor for Caspase-1* , 2002, The Journal of Biological Chemistry.

[64]  J. Bertin,et al.  The PYRIN domain: a novel motif found in apoptosis and inflammation proteins , 2000, Cell Death and Differentiation.

[65]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.

[66]  E. Latz,et al.  The Inflammasome: Methods and Protocols , 2022, Methods in Molecular Biology.

[67]  P. A. Crawford,et al.  The ketone metabolite β-hydroxybutyrate blocks NLRP 3 inflammasome – mediated inflammatory disease , 2015 .

[68]  R. Terkeltaub,et al.  Tophus Biology and Pathogenesis of Monosodium Urate Crystal–Induced Inflammation , 2012 .

[69]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[70]  W. Delano The PyMOL Molecular Graphics System , 2002 .

[71]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[72]  M. Heinrich,et al.  Ethnopharmacology of Mexican asteraceae (Compositae). , 1998, Annual review of pharmacology and toxicology.